TWIST1 is a highly conserved basic helix-loop-helix transcription factor that promotes epithelial --mesenchymal transition (EMT). Its misregulation has been observed in various types of tumors. Using the MCF-10A-series of cell lines that recapitulate the early stages of breast cancer formation and EMT, we found TWIST1 to be upregulated during EMT and downregulated early in carcinogenesis. The TWIST1 3 0 UTR contains putative regulatory elements, including miRNA target sites and two cytoplasmic polyadenylation elements (CPE). We found that miR-580, CPEB1, and CPEB2 act as negative regulators of TWIST1 expression in a sequence-specific and additive/cooperative manner.
INTRODUCTION
TWIST1 is a basic helix-loop-helix transcription factor, found throughout the metazoan animal kingdom. TWIST1 has a major role during development in mammals and is an important factor in tumorigenesis. 1 It contributes to metastasis by promoting epithelial --mesenchymal transition (EMT), 2 and is misregulated in a variety of human cancers. 3 TWIST1 is regulated both transcriptionally and post-transcriptionally. Post-transcriptional regulation was first observed in mouse embryos, in which Twist1 mRNA preceeds protein expression in epithelial somites. 4, 5 Similar observations were made in zebrafish. 6 Here, we analyze post-transcriptional regulation of TWIST1 early in tumorigenesis and EMT, using the MCF-10A-based series of cell lines. Spontaneously immortalized MCF-10A mammary epithelial cells 7 have been transformed and further selected, based on their ability to induce tumors and/or metastases, resulting in a series of cell lines that represent early steps of tumorigenesis, 8 --10 providing a valuable tool for analyzing breast cancer development.
Post-transcriptional regulation is typically mediated by regulatory sequences in the 3 0 UTR, including miRNA-binding sites. miRNAs are endogenous small non-coding RNAs that regulate gene expression, primarily by inhibiting protein synthesis, either by repressing translation and/or by deadenylation, and subsequent degradation of mRNA. 11 Cytoplasmic polyadenylation was initially described as a mechanism that regulates the expression of genes involved in cell-cycle control during early embryogenesis. 12 This mechanism has also been shown to control poly(A) tail length in mammalian cells. 13, 14 Cytoplasmic polyadenylation is mediated by cytoplasmic polyadenylation binding protein (CPEB), which binds to the highly conserved cytoplasmic polyadenylation element (CPE) in the 3 0 UTR of mRNA. 15 Here, we show that CPEB1 and CPEB2 play a role in the translational control of TWIST1 in a CPE-dependent manner.
Moreover, miR-580 targets the 3 0 UTR of TWIST1, controls TWIST1 expression, and affects cell migration. Closely located CPE-I and miR-580 sites have additive and cooperative effects on TWIST1 expression.
RESULTS AND DISCUSSION
TWIST1 expression during breast cancer development MCF-10A (termed A10 in the figures) cells originate from spontaneously immortalized non-malignant human mammary epithelial cells after long-term cultures of mortal human diploid mammary epithelial cells from a patient with extensive fibrocystic disease. 7 Transformation of MCF-10A cells with an activated H-Ras oncogene resulted in premalignant MCF-10AT/MCF-10ANeoT cells (termed NeoT in the figures) 16 that never form tumors, but do form preneoplastic lesions in immunodeficient mice. 8, 17 Subsequent serial xenografting in mice created MCF-10CA1a cells (termed CA1a in the figures). 8 These cells yielded a 100% incidence of tumors when transplanted into nude mice. 10 Stable transduction of MCF-10ANeoT cells with Y-box binding protein 1 YB-1 (MCF-10ANeoT-YB-1, termed YB-1 in figures) induced EMT. 9 YB-1 is a known transcriptional and translational regulator, 18 and is a downstream target of TWIST1.
19 Figure 1a shows a schematic summary of the cell lines used.
We confirmed TWIST1 mRNA and protein upregulation during EMT, 9 but observed downregulation in cell lines representing early stages of cancer development (Figures 1b and c; Supplementary  Figure 1a) . This was unexpected, as the upregulation of TWIST1 has been demonstrated in a variety of human cancers, 3 including breast cancer. 20 TWIST1 upregulation, however, has mainly been correlated with aggressive phenotypes, metastasis formation and poor prognosis.
3 TWIST1 is required for cell migration during both development 21 and oncogenesis. 22 Thus, TWIST1 downregulation might help primary tumor cells to remain localized early in breast cancer progression.
Importantly, unlike the early cancer formation model, in which downregulation of TWIST1 at the transcriptional level was quite significant, TWIST1 mRNA levels were barely modified during EMT, whereas the TWIST1 protein was dramatically induced (compare MSCV and YB-1 in Figures 1b and c) . Thus, TWIST1 upregulation cannot be completely accounted for by the upregulation of TWIST1 mRNA, indicating post-transcriptional regulation.
TWIST1 regulation via 3
0 UTR during breast cancer development Post-transcriptional regulation commonly involves protein or RNA binding to the 3 0 UTR of mRNA. Analysis of the TWIST1 3 0 UTR by several algorithms demonstrated a high degree of conservation (87%) between mouse and human sequences (Nairismägi et al., submitted), including four nuclear polyadenylation (pA) signals, the last two of which overlap (pA1-4), two CPEs, and a predicted target site for miR-580 (Figure 1d; Supplementary Figure 2) .
Compared with similarly proliferating non-transformed cells, cancer cells often express substantial quantities of mRNA isoforms with shorter 3 0 UTRs that result from the use of alternative pA signals. 23 By using quantitative PCR (qPCR) primers surrounding the pA2 and pA3/4 signals (nt 464 and 686 from the stop codon, respectively), we found that the TWIST1 3 0 UTR is progressivly shortened in cell lines representing breast cancer development (Figure 1e , left panel). Primers designed for pA1 did not result in the same qPCR efficiency as the pA2 and pA3/4 primers, and were therefore excluded from further analysis. We found that the pA3/4 signal is utilized less efficiently during cancer progression (compare A10 and CA1a cell lines in Figure 1e , right panel) and metastatic transformation (compare MSCV and YB-1 cell lines) than the pA2 signal (67% and 57%, respectively). Shorter forms of the TWIST1 3 0 UTR lack a number of potential regulatory elements (one CPE site and several miRNA target sites), which might lead to deregulated TWIST1 expression during cancer progression.
To investigate the influence of the TWIST1 3 0 UTR on translation efficiency, we used Twist1 3 0 UTR luciferase reporter constructs ending at the pA1, pA2 or pA3/4 signals. For technical reasons, the 3 0 UTR sequence used was from mouse, which has a high homology to the human one (87%). The shorter constructs (ending either at pA1 or pA2) were more efficiently expressed compared with the longest one (pA3) in all cell lines (Figure 1f , left panel), suggesting the existence of negative regulatory elements at the 3 0 -end of the Twist1 3 0 UTR. More importantly, the ratio of luciferase expression between the longest (pA3) and shorter (pA1 and pA2) constructs decreased during cancer progression, but not during EMT (Figure 1f, right panel) . This suggests that the TWIST1 3 0 UTR has an increased inhibitory role during cancer progression, that is counteracted by the decrease in its expression, whereas this phenomenon is not observed during the metastatic process. We therefore postulated that inhibitory factors regulating TWIST1 translation would be upregulated in cell lines that represent early stages of cancer development, but downregulated in a cell line that resembles EMT.
miR-580 controls TWIST1 expression miRNAs are well-known negative regulators of gene expression. To identify candidates that are upregulated in cell lines that recapitulate breast cancer formation and downregulated in a cell line with EMT characteristics, we first analyzed the expression levels of several miRNAs in the MCF-10A-series of cell lines, namely miR-15b*, miR-33a, miR-137, miR-145, miR-151-5p, miR-214*, miR-337-3p, miR-361-5p, miR-450b-5p, miR-508-3p, miR-576-5p, miR-580 and miR-591. Using miRNA-specific qPCR analysis, we identified five miRNAs that fulfilled this requirement to some extent: miR-15b*, miR-137, miR-145, miR-151-5p and miR-580 (Figure 2a) . To address the question of whether these miRNAs are involved in the post-transcriptional regulation of TWIST1, we tested them in reporter assays in MCF-10A cells by co-transfecting a full-length Twist1 3 0 UTR (pA3) luciferase reporter along with a miRNA precursor. The effect of a miRNA was determined relative to full-length 3
0 UTR values, when no miRNA was added (Figure 2b ). Co-transfection with miR-580 resulted in a 36% (Po0.003) downregulation of reporter expression, whereas miR-137 and miR-151-5p yielded a non-significant reduction (24% and 20%, respectively).
To confirm that the inhibition was due to miR-580 binding, we mutated its predicted target site to a restriction enzyme recognition site. This resulted in increased luciferase activity compared with the wild-type (WT) reporter in the absence of exogenous miRNA (Figure 2c ), confirming the predicted target site for miR-580. Moreover, co-transfection of the WT 3 0 UTR reporter, and an antisense inhibitor of miR-580 also resulted in increased luciferase levels, whereas the inhibitor had no effect on the mutated reporter level, demonstrating that endogenous miR-580 is able to target the Twist1 3 0 UTR. Importantly, transfection of miR-580 precursor to MCF-10A cells downregulated the level of endogenous TWIST1 protein, while transfection of anti-miR-580 upregulated its expression (Figure 2d) .
TWIST1 is known for its role in EMT and metastasis formation, 2 processes that require cell migration. To test the influence of miR-580 on TWIST1 functionality, we carried out cell migration assays. Depletion of TWIST1 mRNA in MCF-10ANeoT-MSCV cells by short interfering RNA (siRNA) led to a 23% decrease in cell motility (Figure 2e ). This reduction was even greater when miR-580 precursor was introduced into the cells (57%), indicating that miR-580 is a negative regulator of cell motility and might at least partially act via regulation of TWIST1.
Interestingly, miR-580 has been identified to be among the 20 most abundant miRNAs in breast milk, 24 underlining its probable importance in non-pathological mammary cells. We show here that miR-580 is upregulated in MCF-10ANeoT and MCF-10CA1a cells and downregulated in MCF-10ANeoT-YB1 cells, which have undergone EMT. This expression pattern, which is opposite to that of TWIST1, is compatible with the idea that miR-580 regulates TWIST1 during breast cancer formation and EMT. Indeed, the fact that overexpression of miR-580 and downregulation of TWIST1 both inhibit cell motility suggests that miR-580 functions during metastatic transformation.
CPEBs control TWIST1 expression through CPEs in its 3
0 UTR The 3 0 UTR of TWIST1 also contains two CPE signals located at nt 334 (CPE-I) and 640 (CPE-II) from the stop codon. We hypothesized that CPEBs could be involved in TWIST1 regulation. The CPEB gene family consists of four members, CPEB1-4. Using qPCR and western blot analyses, we first measured the mRNA and protein levels of all four CPEBs in MCF-10A-derived cell lines. We found that the CPEB family members were regulated in different ways: CPEB1 and CPEB3 mRNA (Figure 3a) and protein (Figure 3b ; Supplementary Figure 1B) were downregulated during cancer progression and EMT, whereas CPEB2 and CPEB4 were upregulated, compared with GAPDH mRNA and Tubulin protein, which were used as internal standards. The latter were thus inversely correlated with TWIST1 expression in cell lines that recapitulate the early stages of breast cancer formation, whereas CPEB1 and CPEB3 were inversely correlated with TWIST1 during a metastatic process.
To determine whether any of the CPEBs regulate TWIST1 expression, we carried out gain-and loss-of-function experiments. The full-length Twist1 3 0 UTR reporter was co-transfected with expression vectors encoding CPEB1-4 or siRNAs against CPEBs. The efficiency of the various siRNAs was tested by qPCR analysis (Supplementary Figure 1C) . A 3 0 UTR reporter construct, in which the two CPEs were mutated (mut-CPE-I þ II), was used as a control. Overexpression of CPEB1 and CPEB2 resulted in decreased luciferase activity, whereas CPEB3 and CPEB4 had no effect (Figure 3c, left panel) . None of the CPEBs had any effect on the CPE mutant reporter (Figure 3c, right panel) . Knockdown of endogenous CPEB1 and CPEB2 with siRNAs led to increased luciferase expression by the WT 3 0 UTR vector (Figure 3d , left panel). Consistent with the gain-of-function experiments, depletion of CPEB3 and CPEB4 had no effect on the expression of the WT Twist1 3 0 UTR reporter. None of the CPEB siRNAs affected the expression of the mut-CPE-I þ II reporter (Figure 3d, right panel) . This suggests that only CPEB1 and CPEB2 are able to mediate Twist1 regulation in a CPE-dependent manner. Importantly, overexpression of CPEB1 and CPEB2 downregulated the endogenous TWIST1 protein level in MCF-10A cells, whereas siRNA knockdown of CPEB1 and CPEB2 upregulated TWIST1 expression (Figure 3e) .
To verify whether CPEB1 and CPEB2 were able to bind to TWIST1 mRNA, we carried out CPEB RNA immunoprecipitation assays. After transfecting HeLa cells with CPEB1-4 constructs fused to Flag tag, we immunoprecipitated the CPEB proteins with anti-Flag antibodies and eluted them with Flag peptide. TWIST1 mRNA was detected by qPCR. TWIST1 mRNA was associated with CPEB2, and to a lesser extent, with CPEB1 and CPEB3, but apparently not with CPEB4 ( Figure 3f ).
To identify which of the two CPEs was important for CPEBmediated TWIST1 regulation, we analyzed the expression of Twist1 3 0 UTR mutant reporters that lack the CPEs (either individually or in combination). As shown in Figure 4a , deletion of each individual CPE increased luciferase activity approximately twofold compared with the WT reporter, whereas a mutation of both sites resulted in almost tenfold higher luciferase expression, indicating that the both CPEs are involved in Twist1 regulation, possibly with synergistic effects.
To find out which of the CPEs was responsible for CPEB1 and CPEB2 binding, we used each individual CPE mutant in combination with CPEB downregulation. The construct that included only CPE-II (mut-CPE-I) was influenced by siCPEB1 and siCPEB2 (Figure 4b, left panel) , whereas the construct that included only CPE-I (mut-CPE-II) was sensitive only to siCPEB1 (Figure 4b , right panel). This suggests that CPE-I in the 3 0 UTR of Twist1 is a target only for CPEB1-mediated regulation, whereas CPE-II is a target for both CPEB1 and CPEB2. CPEB1 and CPEB2 have been shown to bind to the 3 0 UTR of hypoxia-inducible factor 1a and are involved in positive regulation of hypoxia-inducible factor 1a following insulin stimulation.
25
TWIST1 is a known hypoxia-inducible factor 1a target gene, and both are highly relevant in EMT and metastasis formation in head and neck squamous cell carcinoma 26 and non-small-cell lung cancer. 27 It would therefore be of interest to test CPEB levels under hypoxic conditions. Nevertheless, our observations, as well as those of others, 15 indicate that CPEB proteins are not functionally identical.
Because of the close proximity of CPE-I and miR-580 target sites in the 3 0 UTR of TWIST1, we hypothesized that these regulatory mechanisms might act cooperatively. To test this, we transfected MCF-10A cells with CPEB1 and miR-580 both individually and in combination. Individual transfection of CPEB led to 46% and miR-580 to 32% downregulation of the WT 3 0 UTR reporter, whereas co-transfection of both factors led to a 90% decrease in luciferase activity (Figure 4c ), indicating that they have an additive, or possibly a cooperative, effect. Importantly, co-transfection of premiR-580 along with CPEB1 downregulated the endogeneous TWIST1 protein level more than transfection of each factor separately, and co-transfection of anti-miR-580 and siCPEB1 upregulated TWIST1 expression to a higher level than either of them alone (Figure 4d ).
In sum, we have shown that TWIST1 is downregulated early in carcinogenesis and upregulated in metastatic cells, as demonstrated in this series of MCF-10A-derived cell lines. The TWIST1 3 0 UTR is shortened during cancer progression and EMT. We identified miR-580, CPEB1 and CPEB2 as negative regulators of TWIST1 and demonstrated cooperative effects between the CPE-I and miR-580 sites. Moreover, miR-580 is not only able to target the 3 0 UTR of TWIST1 and to control TWIST1 expression, it also affects cell migration. In addition, we have shown that CPEB2 binds only to CPE-II, which is not present in the short form of TWIST1 mRNA expressed in metastatic cells. This correlates with high TWIST1 expression and indicates that CPEB2 is important in regulating TWIST1 expression during oncogenesis.
